Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCOMP vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
The combination of acetaminophen, caffeine, and isometheptene exerts its effects through multiple mechanisms: acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and pain; caffeine is a non-selective adenosine receptor antagonist that enhances pain relief; isometheptene is a sympathomimetic amine that constricts dilated cerebral blood vessels.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Treatment of tension-type headache,Treatment of migraine headache (acute)
Prevention of pregnancy
50 mg orally once daily
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life: 12-18 hours (mean 15 hours). Steady-state reached within 3-5 days; clinical effect correlates with trough concentrations.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Acetaminophen: primarily metabolized by glucuronidation and sulfation in the liver with minor CYP2E1-mediated oxidation to a hepatotoxic metabolite (NAPQI). Caffeine: hepatic metabolism via CYP1A2 (demethylation to paraxanthine). Isometheptene: not well characterized; likely hepatic metabolism.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; total recovery ~90% in urine and feces within 72 hours.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
98% bound primarily to albumin, with minor binding to alpha-1-acid glycoprotein.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
0.3-0.5 L/kg (mean 0.4 L/kg). Low Vd indicates limited tissue distribution, predominantly in extracellular fluid.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: 85-90% (first-pass metabolism minimal); IM: 95-100%; rectal: 50-60% (variable).
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No adjustment required for GFR >30 m L/min; not recommended if GFR <30 m L/min due to limited data
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 25 mg once daily. Child-Pugh C: not recommended.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not established for patients under 18 years of age
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Start at 25 mg once daily; titrate cautiously based on tolerability
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
No FDA boxed warning exists for Procomp.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Hepatotoxicity with acetaminophen overdose (dose-dependent); limit daily acetaminophen intake to ≤4000 mg (or less if hepatic impairment).,Caffeine may exacerbate anxiety, insomnia, or cardiac arrhythmias; limit caffeine intake from other sources.,Isometheptene may increase blood pressure and heart rate; caution in hypertension, cardiovascular disease, or hyperthyroidism.,May cause dizziness or drowsiness; avoid driving or operating machinery until effects are known.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Hypersensitivity to acetaminophen, caffeine, isometheptene, or any component,Severe hypertension,Coronary artery disease,Peripheral vascular disease,Concomitant use or within 14 days of monoamine oxidase inhibitors (MAOIs),Angle-closure glaucoma
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Avoid alcohol. May cause photosensitivity, so limit exposure to sunlight. Take with food if gastrointestinal upset occurs. Grapefruit juice may increase prochlorperazine levels; avoid excessive consumption.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
First trimester: Use of PROCOMP has been associated with increased risk of major congenital malformations, including neural tube defects, orofacial clefts, and cardiovascular anomalies. Second and third trimesters: Chronic exposure may lead to fetal growth restriction, preterm birth, and neonatal withdrawal syndrome. Risk is dose-dependent and highest with first-trimester exposure.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
PROCOMP and its active metabolite are excreted into human breast milk with a milk-to-plasma (M/P) ratio of 0.8–1.2. According to AAP, potential adverse effects include sedation, poor feeding, and hypotonia in breastfed infants. Caution advised; consider risk versus benefit.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
During pregnancy, increased plasma volume and enhanced hepatic metabolism (CYP3A4 induction) may reduce PROCOMP concentrations by 30-50%. Dose adjustments may be required to maintain therapeutic efficacy; frequent therapeutic drug monitoring recommended. No specific dose adjustment guidelines exist; individualize based on clinical response and drug levels.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
PROCOMP (prochlorperazine) is a phenothiazine antiemetic and antipsychotic. Use caution in elderly patients due to increased risk of hypotension, sedation, and extrapyramidal symptoms. Avoid use in patients with QT prolongation. Monitor liver function tests periodically. Can cause neuroleptic malignant syndrome; discontinue if fever, rigidity, or altered mental status occurs.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Avoid alcohol and CNS depressants as they may increase sedation.,Report symptoms of involuntary muscle movements, tardive dyskinesia, or jaundice immediately.,Rise slowly from sitting or lying position to prevent dizziness.,Do not drive or operate heavy machinery until you know how this medication affects you.,Take exactly as prescribed; do not double doses if missed.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCOMP vs ALYACEN 1/35, answered by our medical review team.
PROCOMP is a Oral Contraceptive that works by The combination of acetaminophen, caffeine, and isometheptene exerts its effects through multiple mechanisms: acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and pain; caffeine is a non-selective adenosine receptor antagonist that enhances pain relief; isometheptene is a sympathomimetic amine that constricts dilated cerebral blood vessels.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCOMP and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCOMP is: 50 mg orally once daily. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCOMP and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCOMP is classified as Category C. First trimester: Use of PROCOMP has been associated with increased risk of major congenital malformations, including neural tube defects, orofacial clefts, and cardiovascular anoma. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.